An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

Junshi Biosciences licensed the exclusive commercial rights for Toripalimab, the Shanghai-based drugmaker's monoclonal ...

Pre-eclampsia dey lead to 70,000 maternal deaths annually, but how e take start still be mystery. Dis article torchlight ...

We recently compiled a list of the 10 Oversold Large Cap Stocks To Buy Now. In this article, we are going to take a look at ...

Detailed price information for Eliem Therapeutics Inc (ELYM-Q) from The Globe and Mail including charting and trades.

We always believe that technology's power can change the biopharmaceutical development pattern. Through the Intelligent Drug ...

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

Regions Conference approved the immunization plan to protect newborns from respiratory syncytial virus (VRS), one of the main ...

Dr John Conibear discusses the changing treatment landscape of NSCLC, durvalumab’s latest approval, and his hopes for future ...

A number of applications benefit from using a high-concentration solution to dilute material in other buffers or solvents. The synthesis method used typically limits the concentration of gold ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

In clinical trials, SA13CA has shown significant efficacy and durable response rates in patients with relapsed or refractory CTCL and PTCL. Additionally, in patients with ALL, SA13CA has demonstrated ...